Medtronic Neuroscience — Goodwill increased by 0.2% to $11.76B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 1.3%, from $11.61B to $11.76B. Over 3 years (FY 2022 to FY 2025), Neuroscience — Goodwill shows relatively stable performance with a 0.9% CAGR.
A decrease in goodwill typically signals an impairment charge, indicating that the value of past acquisitions has declined.
This represents the excess of the purchase price over the fair value of net assets acquired in previous acquisitions wit...
Comparable to goodwill balances reported by peers following M&A activity.
mdt_segment_neuroscience_goodwill| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $11.30B | $11.26B | $11.27B | $11.24B | $11.13B | $11.66B | $11.58B | $11.73B | $11.72B | $11.71B | $11.63B | $11.67B | $11.64B | $11.65B | $11.67B | $11.61B | $11.72B | $11.75B | $11.74B | $11.76B |
| QoQ Change | — | -0.4% | +0.1% | -0.3% | -0.9% | +4.8% | -0.7% | +1.3% | -0.1% | -0.1% | -0.7% | +0.3% | -0.3% | +0.1% | +0.1% | -0.5% | +0.9% | +0.3% | -0.1% | +0.2% |
| YoY Change | — | — | — | — | -1.5% | +3.6% | +2.8% | +4.4% | +5.3% | +0.4% | +0.5% | -0.5% | -0.6% | -0.5% | +0.3% | -0.5% | +0.6% | +0.9% | +0.6% | +1.3% |